At the dawn of 2026, amid the snow-covered peaks of Davos, where the world’s elite convene each year, a rallying call reverberated through the Swiss Alps from a country more readily associated with consensus than conviction. It was Canadian Prime Minister Mark Carney who plainly named the mokita at the heart of global politics: With the rules-based international order fracturing and the world entering “a state of rupture,” middle powers can no longer afford to retreat into the shadows.

This is an extraordinary moment for the sector. The jump in our understanding of the human genome and the emergence of AI have led to science and therapies that are changing how serious diseases are treated including cancer, diabetes, and many neuromuscular diseases.

Canada has a long history of being at the forefront of medical innovation. Insulin is a point of pride, but there was also whooping cough research and the Toronto method for the polio vaccine. Today we’re leading in radiopharmaceuticals, genomics, cell and gene therapy, regenerative medicine, and AI-driven drug discovery.

Canada has the science and companies, but the next stage requires stronger capital pathways and more competitive routes to market.

We work to connect Canadian companies with investors, partners, and market opportunities abroad while also attracting investment and partnerships into Canada